BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21280201)

  • 21. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).
    Paulides M; Kremers A; Stöhr W; Bielack S; Jürgens H; Treuner J; Beck JD; Langer T;
    Pediatr Blood Cancer; 2006 Apr; 46(4):489-95. PubMed ID: 16333817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.
    Shankar SM; Marina N; Hudson MM; Hodgson DC; Adams MJ; Landier W; Bhatia S; Meeske K; Chen MH; Kinahan KE; Steinberger J; Rosenthal D;
    Pediatrics; 2008 Feb; 121(2):e387-96. PubMed ID: 18187811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth-differentiation factor-15 and tissue doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors.
    Arslan D; Cihan T; Kose D; Vatansev H; Cimen D; Koksal Y; Oran B; Akyurek F
    Clin Biochem; 2013 Sep; 46(13-14):1239-43. PubMed ID: 23850849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
    Elbl L; Hrstkova H; Chaloupka V; Novotny J; Michalek J
    Neoplasma; 2003; 50(3):191-7. PubMed ID: 12937852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
    van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer].
    Oberholzer K; Kunz RP; Dittrich M; Thelen M
    Rofo; 2004 Sep; 176(9):1245-50. PubMed ID: 15346258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
    Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
    Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
    Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
    Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cohort of long-term survivors at the German childhood cancer registry.
    Debling D; Spix C; Blettner M; Michaelis J; Kaatsch P
    Klin Padiatr; 2008; 220(6):371-7. PubMed ID: 18949673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
    Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
    J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exercise recommendations for childhood cancer survivors exposed to cardiotoxic therapies: an institutional clinical practice initiative.
    Okada M; Meeske KA; Menteer J; Freyer DR
    J Pediatr Oncol Nurs; 2012; 29(5):246-52. PubMed ID: 22907680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
    Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
    Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H; Nielsen G
    Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.
    Landier W; Bhatia S; Eshelman DA; Forte KJ; Sweeney T; Hester AL; Darling J; Armstrong FD; Blatt J; Constine LS; Freeman CR; Friedman DL; Green DM; Marina N; Meadows AT; Neglia JP; Oeffinger KC; Robison LL; Ruccione KS; Sklar CA; Hudson MM
    J Clin Oncol; 2004 Dec; 22(24):4979-90. PubMed ID: 15576413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity of health conditions identified in a pediatric cancer survivor program.
    Wasilewski-Masker K; Mertens AC; Patterson B; Meacham LR
    Pediatr Blood Cancer; 2010 Jul; 54(7):976-82. PubMed ID: 20108334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
    Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
    J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.
    MacArthur AC; Spinelli JJ; Rogers PC; Goddard KJ; Phillips N; McBride ML
    Pediatr Blood Cancer; 2007 Apr; 48(4):453-9. PubMed ID: 16767718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.